Overview: NGS CPEO Panel Sequencing TestIntroduction: The NGS CPEO Panel Sequencing Test sequences genes to diagnose chronic progressive external ophthalmoplegia (CPEO), causing eye muscle weakness. Aligned with 2023 AAN guidelines, it uses PCR for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected CPEO.
Other Names: CPEO NGS Assay, POLG/TWNK Gene Panel.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: CPEO sequencing began in the 2000s with mitochondrial disorder research. NGS methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Sequences genes to diagnose CPEO, guides treatment, and evaluates patients with eye muscle weakness.
Test Parameters: 1. CPEO Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of eye muscle weakness, ptosis, or CPEO symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document eye muscle weakness, ptosis, diplopia, or family history of CPEO. Include current medications, especially mitochondrial therapies.
Consent: Written consent required, detailing the tests purpose, CPEO implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to analyze CPEO genes (e.g., POLG, TWNK). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for CPEO diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm CPEO, guiding supportive care or genetic counseling. Negative results may require mitochondrial DNA testing.
Specialist Consultation: Consult a neurologist or geneticist for result interpretation and treatment planning.
Additional Supporting Tests: Muscle biopsy, EMG, or brain MRI to confirm CPEO diagnosis.
Test Limitations: Not all CPEO cases are genetic; clinical correlation is needed. Sample quality affects sensitivity.
References: AAN CPEO Guidelines, 2023; Neurology, Mancuso M, 2022.
